Showing results (391-400 of 587) with videos related to
Sort By:
Pageof 59
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLCLuc Friboulet, Daniel Barrios-Gonzales, Frédéric Commo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.Journal of Crohn'S & Colitis|October 3, 2017
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological EntitiesClélia Coutzac, Julien Adam, Emilie Soularue, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.European Journal of Cancer (Oxford, England : 1990)|November 23, 2025
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapyCaroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, et al.Clinical Lung Cancer|September 30, 2022
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France StudyPierre Mordant, Solenn Brosseau, Bernard Milleron, et al.Future Oncology (London, England)|February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancerMarina C Garassino, Luis Paz-Ares, Rina Hui, et al.Pageof 59